IBRX · ImmunityBio, Inc.
$8.05
-0.35 (-4.17%)
At close · Aug 28
Going-concern doubt
— cleared Aug 4, 2026
The latest filing states the doubt was alleviated.
“we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash and cash equivalents, and investments in marketable securities; sales of our approved product; capital to be raised through equity offerings, including but not limited to, the offering, issuance and sale by us of our common stock under our Form S-3ASR shelf registration statement; and our potential ability to borrow from affiliated entities will be sufficient to fund our operations through at least the next 12 months following the issuance date of the condensed consolidated financial statements based primarily upon our Founder, Executive Chairman and Global Chief Scientific and Medical Officer's intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt.”View the 10-Q filed Aug 4, 2026
Market Cap
$8.90B
Shares
1.06B
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$113.29M
+668.3%
FY2025
Net Income
-$351.4M
+15%
FY2025
Gross Margin
99.34%
-0.7pp
FY2025
Operating Margin
-226%
+2108.2pp
FY2025
Diluted EPS
-$0.38
+38.7%
FY2025
Operating Cash Flow
-$304.94M
+22.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $165.79M | $113.29M | $14.75M | $622K | $240K | $934K | $605K | $2.2M | $47K | $45K | $44K | $236K | $641K | $600K | |
| $1.1M | $753K | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| $164.7M | $112.54M | $14.75M | $622K | $240K | — | — | — | — | — | — | — | — | — | |
| — | 99.34% | 100% | 100% | 100% | — | — | — | — | — | — | — | — | — | |
| — | — | $190.14M | $232.37M | $248.15M | $195.96M | $139.51M | $112M | $55.72M | $42.04M | $29.15M | $11.43M | $1.6M | $446K | |
| — | — | $168.78M | $129.62M | $102.71M | $135.26M | $71.32M | $46.46M | $42.72M | $57.12M | $95.39M | $227.68M | $4.62M | $2.42M | |
| $2M | — | $2M | $2M | $1.9M | — | — | $600K | $2.3M | $2.3M | $2.6M | $1.3M | $0 | — | |
| $16.6M | $15.53M | $17.55M | $18.51M | $18.26M | $14.24M | $12.74M | $14.04M | $9.56M | $5.57M | $3.61M | $1.47M | $36K | $4000 | |
| — | — | $358.93M | $362.87M | $351.54M | $331.21M | $221.49M | $158.45M | $98.44M | $99.17M | $124.54M | $239.11M | $6.22M | — | |
| $417.59M | $369.32M | $358.93M | $362.87M | — | — | — | — | — | — | — | — | — | — | |
| -$251.8M | -$256.03M | -$344.18M | -$362.25M | -$351.3M | -$330.28M | -$220.88M | -$156.25M | -$98.39M | -$99.12M | -$124.5M | -$238.88M | -$5.58M | — | |
| — | -226% | -2334.23% | -58239.55% | -146374.17% | -35361.88% | -36509.09% | -7095.87% | -209338.3% | -220266.67% | -282954.55% | -101218.64% | -869.73% | — | |
| -$235.2M | -$240.5M | -$326.63M | -$343.74M | -$333.04M | -$316.04M | -$208.14M | -$142.21M | -$88.83M | -$93.55M | -$120.89M | -$237.4M | -$5.54M | — | |
| — | $60.89M | $114.59M | $128.85M | $63.52M | $14.85M | $9.07M | $5.92M | — | $618K | $66K | $0 | $471K | $463K | |
| $1.74M | — | — | — | — | — | $1.23M | $1.64M | $2.32M | $4.23M | $5.17M | $312K | $20K | $2000 | |
| -$740.78M | -$95.58M | -$69.46M | -$221.64M | -$65.99M | -$19.56M | -$5.15M | -$4.01M | $1.66M | $2.2M | $3.12M | $1.7M | -$609K | — | |
| — | $0 | $0 | -$7.55M | -$12.11M | -$803K | $0 | $0 | — | $0 | $0 | -$56K | $0 | — | |
| $9.83M | $6.41M | $7.98M | $1.13M | -$3.09M | -$4.1M | $2.44M | $2.44M | — | — | — | — | — | — | |
| -$992.58M | -$351.61M | -$413.65M | -$583.89M | -$417.29M | -$349.84M | -$226.03M | -$160.26M | -$96.73M | -$96.92M | -$121.38M | -$237.18M | -$6.18M | — | |
| -$161K | -$135K | $0 | -$40K | $34K | $9000 | -$1.85M | -$105K | -$503K | -$493K | -$572K | -$301K | $1000 | $1000 | |
| -$992.34M | -$351.4M | -$413.56M | -$583.2M | -$416.57M | -$346.79M | -$221.85M | -$157.78M | -$96.23M | -$96.42M | -$120.81M | -$236.88M | -$6.19M | -$2.05M | |
| — | -310.18% | -2804.77% | -93761.41% | -173569.58% | -37129.55% | -36669.59% | -7165.17% | -204736.17% | -214273.33% | -274565.91% | -100371.19% | -964.9% | -341.17% | |
| -$62K | -$74K | -$81K | -$656K | -$753K | -$3.06M | -$2.34M | -$2.38M | — | — | — | — | — | — | |
| -$992.36M | -$351.4M | -$413.56M | -$583.2M | -$416.57M | — | — | — | — | — | — | — | — | — | |
| -$977.64M | -$323.64M | -$412.38M | -$583.37M | -$416.39M | -$346.91M | -$92.4M | -$65.63M | -$96.11M | -$96.52M | -$120.9M | -$237.07M | -$6.19M | -$2.05M | |
| USD/shares | -$0.97 | -$0.38 | -$0.59 | -$1.15 | -$1.04 | -$0.89 | -$0.59 | -$0.43 | — | — | — | — | — | — |
| USD/shares | -$0.97 | -$0.38 | -$0.62 | -$1.15 | -$1.04 | -$0.89 | -$0.59 | -$0.43 | — | — | — | — | — | — |
| shares | — | 919.86M | 697.31M | 508.64M | 399.9M | 389.23M | 377.07M | 366.32M | 79.13M | 80.58M | 81.98M | 71.52M | 8.25M | 797.11K |
| shares | — | 919.86M | 700.44M | 508.64M | 399.9M | 389.23M | 377.07M | 366.32M | 79.13M | 80.58M | 81.98M | 71.52M | 8.25M | 797.11K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2014–FY2021: $38.6M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 10.30×
EV/EBIT
—
Peer median 28.55×
P/E (TTM)
—
Peer median 19.80×
Peer medians compare against the 151 similar-size Biotechnology companies (of 524 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $113,288,000 | $14,745,000 | $622,000 | $240,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| United States | $113,010,000 | $14,214,000 | $31,000 | $42,000 | $373,000 | $513,000 | $1,997,000 |
| Europe | $278,000 | $531,000 | $591,000 | $198,000 | $561,000 | $92,000 | $205,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Product | $112,982,000 | $14,150,000 | $0 | $0 |
| Product And Service Other | $306,000 | $595,000 | $622,000 | $240,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$256,027,000 | -$344,182,000 | -$362,250,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -226% | -2334.2% | -58239.5% |
Key facts
CIK
1326110
CUSIP
45256X103
13F (30d)
306 filings
293 filers
Visit website
Investor relations